Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
Highlights
► Cytokines are critical contributors to autoimmune disease, cancer, and other diseases. ► Janus kinases (Jaks) selectively associate with type I and II cytokine receptors. ► Jaks have essential, nonredundant roles in mediating signals via these receptors. ► Ruxolitinib is approved for treatment of myelofibrosis, a disorder associated with Jak2 mutations. ► Tofacitinib has shown efficacy in trials in rheumatoid arthritis and other autoimmune diseases.
Introduction
Enabled by advances in molecular biology, it is now clear that an array of cytokines controls the growth and differentiation of hematopoietic cells and orchestrate all aspects of immune response [1]. From the differentiation of stem cells to the inciting events precipitated by activation of innate immune cells and the fine-tuning of helper T cell responses, cytokines play pivotal roles. However, cytokines are also fundamentally important for immune-mediated disease. A large segment of the population of industrialized countries suffers from asthma and allergy and a range of autoimmune diseases. In addition though, it is increasingly recognized that inflammation and dysregulation of cytokine production are directly involved in the pathophysiology of many other diseases including atherosclerosis and metabolic syndrome, degenerative neurologic disease, and cancer. For these reasons, therapeutic targeting of cytokines has immense potential.
The advent of monoclonal antibody technology and the ability to create therapeutically useful recombinant cytokine receptors has dramatically changed the therapeutic landscape of a wide variety of diseases. Thanks to ‘biologics’ debilitating diseases like rheumatoid arthritis (RA), which were previously associated with inexorable joint destruction, can be effectively treated. The question then arises: can the actions of cytokines be blocked by targeting intracellular signal transduction? In other words, might a pill be as efficacious as a parenteral biologic?
Section snippets
Janus kinases and signaling by type I/II cytokine receptors
The family of cytokines that bind type I and type II cytokine receptors includes interleukins, interferons, and colony-stimulating factor, as well as classic hormones such as erythropoietin, prolactin, and growth hormone [2]. Signaling via these receptors is dependent upon a small family of structurally distinct kinases with apparently circumscribed function (Figure 1). The Janus family of kinases (Jaks) comprises four members Tyk2, Jak1, Jak2, and Jak3 [3], which selectively associate with
Feasibility of kinases as therapeutic targets
At that time though, it was by no means a given that kinases were good therapeutic targets. Recall that this work preceded our present understanding of the human kinome. Of course, we now know that there are 518 kinases that can be divided into eight distinct families. Jaks belong to the tyrosine protein kinase family of which there are 90 other members. Because of the conserved kinase domain structure, it might be assumed that attaining the needed specificity to inhibit a certain kinase would
Targeting Janus kinases in autoimmune diseases and transplant rejection
The first selective jakinib to be tested in humans was tofacitinib (formerly designated CP-690,550). Tofacitinib potently inhibits Jak3 (IC 50, 2.2 nm) and Jak1 and to a lesser extent Jak2 (IC 50, 5.0 nm). It has little effect on Tyk2 (IC 50 260 nm) [20]. Remarkably, tofacitinib has potent activity against Jaks with little effect on other kinases [21•].
The utility of tofacitinib as an immunomodulatory drug was established in a variety of transplant models (murine and nonhuman primates) [22, 23] as
Targeting Jaks in myelofibrosis and polycythemia vera
A breakthrough in understanding the pathogenesis of the myeloproliferative diseases, polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) was the discovery of gain-of-function JAK2 mutations [47]. All of these mutations reside in the regulatory kinase-like domain, which has recently been found to have enzymatic activity [48]. In view of the success of imatinib in the treatment of CML, it was logical to consider that the development of a Jak2 inhibitor would be
Conclusions
Despite potential challenges, kinase inhibitors have emerged as an exciting new class of drugs. Given the key role of cytokines in many disorders ranging from malignancy to autoimmunity, Jak inhibitors or Jakinibs have the potential for wide utility in a range of diseases. They have demonstrated efficacy in PV/MF and an array of common autoimmune disorders. The extent to which Jakinibs will be used as steroid-sparing agents or even supplant the use of steroids in diseases like the vasculitides
References and recommended reading
Papers of particular interest, published within the period of review, have been highlighted as:
• of special interest
•• of outstanding interest
References (65)
- et al.
Molecular phylogeny within type I cytokines and their cognate receptors
Immunity
(2003) - et al.
Sharing of a common gamma chain, gamma c, by the IL-2, IL-4, and IL-7 receptors: implications for X-linked severe combined immunodeficiency (XSCID)
Adv Exp Med Biol
(1994) - et al.
Janus kinases in immune cell signaling
Immunol Rev
(2009) - et al.
A quantitative analysis of kinase inhibitor selectivity
Nat Biotechnol
(2008) - et al.
Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate
Arthritis Care Res
(2011) - et al.
Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in the treatment of Rheumatoid arthritis: open label, long-term extension studies up to 36 months
Arthritis Rheum
(2011) - et al.
The Jak inhibitor CP-690,550 preserves the function of CD4CD25FoxP3 regulatory T cells and inhibits effector T cells
Am J Transplant
(2010) - et al.
Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2
J Immunol
(2011) - et al.
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia
Nat Genet
(2011) - et al.
Cytokine signaling: birth of a pathway
J Immunol
(2011)
Jaks and STATs: biological implications
Annu Rev Immunol
Jak–STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins
Science
Stats: transcriptional control and biological impact
Nat Rev Mol Cell Biol
A protein tyrosine kinase in the interferon alpha/beta signaling pathway
Cell
Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development
Science
Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)
Nature
Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants
J Pediatr
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
J Clin Invest
Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
J Pharmacol Exp Ther
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
Science
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
N Engl J Med
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
N Engl J Med
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
N Engl J Med
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
Blood
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a ‘head-to-head comparison’
Leuk Lymphoma
Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)
J Immunol
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
Science
The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models
Am J Transplant
Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis
Arthritis Res Ther
Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis
J Invest Dermatol
Phase IIb dose-ranging study of the oral jak inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
Arthritis Rheum
Targeting JAK3 in kidney transplantation: current status and future options
Curr Opin Organ Transplant
Cited by (187)
Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors
2024, European Journal of PharmacologyEngineering immune response to regulate cardiovascular disease and cancer
2024, Advances in Protein Chemistry and Structural BiologyEffect of tofacitinib on clinical and laboratory findings in severe and resistant patients with COVID-19
2023, International ImmunopharmacologyPhytochemicals: recent trends and future prospective in COVID-19
2023, Recent Frontiers of Phytochemicals: Applications in Food, Pharmacy, Cosmetics, and BiotechnologySynthesis and evaluation of hydrazinyl-containing pyrrolo[2,3-d]pyrimidine series as potent, selective and oral JAK1 inhibitors for the treatment of rheumatoid arthritis
2022, Bioorganic and Medicinal Chemistry LettersTofacitinib Suppresses IL-10/IL-10R Signaling and Modulates Host Defense Responses in Human Macrophages
2022, Journal of Investigative Dermatology